Aspire Biopharma Holdings, Inc. Warrant
ASBPW
About: Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
12% more funds holding
Funds holding: 26 [Q1] → 29 (+3) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
33% less capital invested
Capital invested by funds: $630K [Q1] → $420K (-$210K) [Q2]
Financial journalist opinion
We haven’t received any recent news articles for ASBPW